{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:10:51Z","timestamp":1780791051273,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T00:00:00Z","timestamp":1482796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s12265-016-9719-8","type":"journal-article","created":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T15:51:04Z","timestamp":1482853864000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Sirolimus Therapy Is Associated with Elevation in Circulating PCSK9 Levels in Cardiac Transplant Patients"],"prefix":"10.1007","volume":"10","author":[{"given":"Vinaya","family":"Simha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter K.","family":"Kremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liewei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen L.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,27]]},"reference":[{"issue":"6","key":"9719_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/jlts.2001.24645","volume":"7","author":"P Neuhaus","year":"2001","unstructured":"Neuhaus, P., Klupp, J., & Langrehr, J. M. (2001). mTOR inhibitors: an overview. Liver Transplantation, 7(6), 473\u2013484. doi: 10.1053\/jlts.2001.24645 .","journal-title":"Liver Transplantation"},{"issue":"7253","key":"9719_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nature08221","volume":"460","author":"DE Harrison","year":"2009","unstructured":"Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460(7253), 392\u2013395. doi: 10.1038\/nature08221 .","journal-title":"Nature"},{"issue":"8","key":"9719_CR3","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1053\/jlts.2001.26509","volume":"7","author":"T Bak","year":"2001","unstructured":"Bak, T., Wachs, M., Trotter, J., Everson, G., Trouillot, T., Kugelmas, M., et al. (2001). Adult-to-adult living donor liver transplantation using right-lobe grafts: results and lessons learned from a single-center experience. Liver Transplantation, 7(8), 680\u2013686. doi: 10.1053\/jlts.2001.26509 .","journal-title":"Liver Transplantation"},{"issue":"9","key":"9719_CR4","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/00007890-199805150-00023","volume":"65","author":"C Brattstrom","year":"1998","unstructured":"Brattstrom, C., Wilczek, H., Tyden, G., Bottiger, Y., Sawe, J., & Groth, C. G. (1998). Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation, 65(9), 1272\u20131274.","journal-title":"Transplantation"},{"issue":"2","key":"9719_CR5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","volume":"71","author":"AS MacDonald","year":"2001","unstructured":"MacDonald, A. S. (2001). A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation, 71(2), 271\u2013280.","journal-title":"Transplantation"},{"issue":"5","key":"9719_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/jlts.2003.50119","volume":"9","author":"GW Neff","year":"2003","unstructured":"Neff, G. W., Montalbano, M., Slapak-Green, G., Berney, T., Bejarano, P. A., Joshi, A., et al. (2003). A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection. Liver Transplantation, 9(5), 477\u2013483. doi: 10.1053\/jlts.2003.50119 .","journal-title":"Liver Transplantation"},{"issue":"23","key":"9719_CR7","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1161\/CIRCULATIONAHA.107.692996","volume":"116","author":"E Raichlin","year":"2007","unstructured":"Raichlin, E., Bae, J. H., Khalpey, Z., Edwards, B. S., Kremers, W. K., Clavell, A. L., et al. (2007). Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation, 116(23), 2726\u20132733. doi: 10.1161\/CIRCULATIONAHA.107.692996 .","journal-title":"Circulation"},{"issue":"2","key":"9719_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2012.03.003","volume":"222","author":"F Beutner","year":"2012","unstructured":"Beutner, F., Brendel, D., Teupser, D., Sass, K., Baber, R., Mueller, M., et al. (2012). Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice. Atherosclerosis, 222(2), 337\u2013343. doi: 10.1016\/j.atherosclerosis.2012.03.003 .","journal-title":"Atherosclerosis"},{"issue":"25","key":"9719_CR9","doi-asserted-by":"publisher","first-page":"18602","DOI":"10.1074\/jbc.M702027200","volume":"282","author":"DW Zhang","year":"2007","unstructured":"Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., et al. (2007). Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation. The Journal of Biological Chemistry, 282(25), 18602\u201318612. doi: 10.1074\/jbc.M702027200 .","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"9719_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cmet.2013.08.002","volume":"18","author":"DW Lamming","year":"2013","unstructured":"Lamming, D. W., & Sabatini, D. M. (2013). A central role for mTOR in lipid homeostasis. Cell Metabolism, 18(4), 465\u2013469. doi: 10.1016\/j.cmet.2013.08.002 .","journal-title":"Cell Metabolism"},{"issue":"4","key":"9719_CR11","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1172\/jci61919","volume":"122","author":"D Ai","year":"2012","unstructured":"Ai, D., Chen, C., Han, S., Ganda, A., Murphy, A. J., Haeusler, R., et al. (2012). Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. Journal of Clinical Investigation, 122(4), 1262\u20131270. doi: 10.1172\/jci61919 .","journal-title":"Journal of Clinical Investigation"},{"key":"9719_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fgene.2013.00166","volume":"4","author":"J Jiang","year":"2013","unstructured":"Jiang, J., Fridley, B. L., Feng, Q., Abo, R. P., Brisbin, A., Batzler, A., et al. (2013). Genome-wide association study for biomarker identification of rapamycin and everolimus using a lymphoblastoid cell line system. Frontiers in Genetics, 4, 166. doi: 10.3389\/fgene.2013.00166 .","journal-title":"Frontiers in Genetics"},{"issue":"13","key":"9719_CR13","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1161\/circulationaha.115.018531","volume":"133","author":"K Leander","year":"2016","unstructured":"Leander, K., Malarstig, A., Van't Hooft, F. M., Hyde, C., Hellenius, M. L., Troutt, J. S., et al. (2016). Circulating proprotein convertase subtilisin\/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors. Circulation, 133(13), 1230\u20131239. doi: 10.1161\/circulationaha.115.018531 .","journal-title":"Circulation"},{"issue":"22","key":"9719_CR14","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1007\/s00018-014-1677-1","volume":"71","author":"D Ehninger","year":"2014","unstructured":"Ehninger, D., Neff, F., & Xie, K. (2014). Longevity, aging and rapamycin. Cellular and Molecular Life Sciences, 71(22), 4325\u20134346. doi: 10.1007\/s00018-014-1677-1 .","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"2","key":"9719_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00395-015-0463-z","volume":"110","author":"R Schulz","year":"2015","unstructured":"Schulz, R., Schluter, K. D., & Laufs, U. (2015). Molecular and cellular function of the proprotein convertase subtilisin\/kexin type 9 (PCSK9). Basic Research in Cardiology, 110(2), 4. doi: 10.1007\/s00395-015-0463-z .","journal-title":"Basic Research in Cardiology"},{"issue":"2","key":"9719_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2014.12.017","volume":"238","author":"H Tavori","year":"2015","unstructured":"Tavori, H., Rashid, S., & Fazio, S. (2015). On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis, 238(2), 264\u2013270. doi: 10.1016\/j.atherosclerosis.2014.12.017 .","journal-title":"Atherosclerosis"},{"issue":"8","key":"9719_CR17","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1016\/j.transproceed.2003.10.002","volume":"35","author":"GW Neff","year":"2003","unstructured":"Neff, G. W., Montalbano, M., Slapak-Green, G., Meyer, D., Berney, T., Safdar, K., et al. (2003). Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplantation Proceedings, 35(8), 3029\u20133031.","journal-title":"Transplantation Proceedings"},{"issue":"5","key":"9719_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1053\/jlts.2001.23916","volume":"7","author":"JF Trotter","year":"2001","unstructured":"Trotter, J. F., Wachs, M. E., Trouillot, T. E., Bak, T., Kugelmas, M., Kam, I., et al. (2001). Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transplantation, 7(5), 401\u2013408. doi: 10.1053\/jlts.2001.23916 .","journal-title":"Liver Transplantation"},{"issue":"2","key":"9719_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2014.07.010","volume":"236","author":"BJ Arsenault","year":"2014","unstructured":"Arsenault, B. J., Pelletier-Beaumont, E., Almeras, N., Tremblay, A., Poirier, P., Bergeron, J., et al. (2014). PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program. Atherosclerosis, 236(2), 321\u2013326. doi: 10.1016\/j.atherosclerosis.2014.07.010 .","journal-title":"Atherosclerosis"},{"issue":"7","key":"9719_CR20","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1210\/jc.2009-0141","volume":"94","author":"SG Lakoski","year":"2009","unstructured":"Lakoski, S. G., Lagace, T. A., Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2009). Genetic and metabolic determinants of plasma PCSK9 levels. Journal of Clininical Endocrinology & Metabolism, 94(7), 2537\u20132543. doi: 10.1210\/jc.2009-0141 .","journal-title":"Journal of Clininical Endocrinology & Metabolism"},{"issue":"1","key":"9719_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/circulationaha.115.020912","volume":"134","author":"ME Haas","year":"2016","unstructured":"Haas, M. E., Levenson, A. E., Sun, X., Liao, W. H., Rutkowski, J. M., de Ferranti, S. D., et al. (2016). The role of proprotein convertase subtilisin\/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation, 134(1), 61\u201372. doi: 10.1161\/circulationaha.115.020912 .","journal-title":"Circulation"},{"issue":"8","key":"9719_CR22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","volume":"43","author":"JD Morrisett","year":"2002","unstructured":"Morrisett, J. D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C. M., Pownall, H. J., et al. (2002). Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. Journal of Lipid Research, 43(8), 1170\u20131180.","journal-title":"Journal of Lipid Research"},{"issue":"8","key":"9719_CR23","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0041-1345(00)01884-4","volume":"32","author":"MD Tur","year":"2000","unstructured":"Tur, M. D., Garrigue, V., Vela, C., Dupuy, A. M., Descomps, B., Cristol, J. P., et al. (2000). Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. Transplantation Proceedings, 32(8), 2783\u20132784.","journal-title":"Transplantation Proceedings"},{"key":"9719_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biocel.2015.01.011","volume":"61","author":"J Liu","year":"2015","unstructured":"Liu, J., Ma, K. L., Zhang, Y., Wu, Y., Hu, Z. B., Lv, L. L., et al. (2015). Activation of mTORC1 disrupted LDL receptor pathway: a potential new mechanism for the progression of non-alcoholic fatty liver disease. The International Journal of Biochemistry & Cell Biology, 61, 8\u201319. doi: 10.1016\/j.biocel.2015.01.011 .","journal-title":"The International Journal of Biochemistry & Cell Biology"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-016-9719-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12265-016-9719-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-016-9719-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T08:26:00Z","timestamp":1601281560000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12265-016-9719-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["9719"],"URL":"https:\/\/doi.org\/10.1007\/s12265-016-9719-8","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,27]]}}}